MA52631A - Compositions et méthodes pour le traitement de la maladie de parkinson - Google Patents

Compositions et méthodes pour le traitement de la maladie de parkinson

Info

Publication number
MA52631A
MA52631A MA052631A MA52631A MA52631A MA 52631 A MA52631 A MA 52631A MA 052631 A MA052631 A MA 052631A MA 52631 A MA52631 A MA 52631A MA 52631 A MA52631 A MA 52631A
Authority
MA
Morocco
Prior art keywords
parkinson
disease
compositions
treatment
methods
Prior art date
Application number
MA052631A
Other languages
English (en)
Inventor
Adrian Philip Kells
Bernard Ravina
Original Assignee
Voyager Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voyager Therapeutics Inc filed Critical Voyager Therapeutics Inc
Publication of MA52631A publication Critical patent/MA52631A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MA052631A 2018-05-15 2019-05-15 Compositions et méthodes pour le traitement de la maladie de parkinson MA52631A (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862671944P 2018-05-15 2018-05-15
US201862681891P 2018-06-07 2018-06-07
US201862684384P 2018-06-13 2018-06-13
US201862691748P 2018-06-29 2018-06-29
US201862698419P 2018-07-16 2018-07-16
US201862703137P 2018-07-25 2018-07-25
US201862741021P 2018-10-04 2018-10-04
US201862748119P 2018-10-19 2018-10-19
US201862756897P 2018-11-07 2018-11-07
US201962789909P 2019-01-08 2019-01-08
US201962831400P 2019-04-09 2019-04-09

Publications (1)

Publication Number Publication Date
MA52631A true MA52631A (fr) 2021-03-24

Family

ID=67060450

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052631A MA52631A (fr) 2018-05-15 2019-05-15 Compositions et méthodes pour le traitement de la maladie de parkinson

Country Status (13)

Country Link
US (1) US20210198691A1 (fr)
EP (1) EP3794126A1 (fr)
JP (1) JP2021523914A (fr)
KR (1) KR20210019996A (fr)
CN (1) CN112424359A (fr)
AU (1) AU2019268330A1 (fr)
BR (1) BR112020023082A2 (fr)
CA (1) CA3099306A1 (fr)
MA (1) MA52631A (fr)
MX (1) MX2020012077A (fr)
SG (1) SG11202011296VA (fr)
TW (1) TW202012628A (fr)
WO (1) WO2019222328A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202007103TA (en) 2014-11-05 2020-09-29 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
EP4219724A3 (fr) 2016-08-23 2023-09-27 Akouos, Inc. Compositions et procédés pour traiter une déficience auditive non associée au vieillissement chez un sujet humain
WO2018191450A2 (fr) 2017-04-14 2018-10-18 National Taiwan University Hospital Thérapie génique pour une carence en aadc
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
WO2021007382A1 (fr) * 2019-07-09 2021-01-14 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement de la maladie de parkinson
CA3168055A1 (fr) 2020-02-21 2021-08-26 Emmanuel John Simons Compositions et methodes de traitement d'une hypoacousie non associee a l'age chez un sujet humain
CN115607684A (zh) * 2021-07-15 2023-01-17 华中科技大学 一种内耳药物纳米载体及其应用
CN116554278A (zh) * 2022-01-30 2023-08-08 上海玮美基因科技有限责任公司 变异型腺相关病毒及其在疾病治疗中的应用

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467096A (en) 1966-04-12 1969-09-16 Ferrell S Horn Multiple hypodermic syringe arrangement
BE786542A (fr) 1971-07-22 1973-01-22 Dow Corning Dispositif d'aspiration permettant d'obtenir des echantillons de cellules
US4411657A (en) 1980-05-19 1983-10-25 Anibal Galindo Hypodermic needle
US4474569A (en) 1982-06-28 1984-10-02 Denver Surgical Developments, Inc. Antenatal shunt
US5078140A (en) 1986-05-08 1992-01-07 Kwoh Yik S Imaging device - aided robotic stereotaxis system
FR2640638B1 (fr) 1988-12-20 1991-02-15 Commissariat Energie Atomique Bioreacteur et dispositif pour la culture de cellules animales
US5012818A (en) 1989-05-04 1991-05-07 Joishy Suresh K Two in one bone marrow surgical needle
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5199441A (en) 1991-08-20 1993-04-06 Hogle Hugh H Fine needle aspiration biopsy apparatus and method
US5387484A (en) 1992-07-07 1995-02-07 International Business Machines Corporation Two-sided mask for patterning of materials with electromagnetic radiation
AU5665694A (en) 1992-11-04 1994-05-24 Denver Biomaterials Inc. Apparatus for removal of pleural effusion fluid
FR2703253B1 (fr) 1993-03-30 1995-06-23 Centre Nat Rech Scient Applicateur d'impulsions electriques pour traitement de tissus biologiques.
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5588960A (en) 1994-12-01 1996-12-31 Vidamed, Inc. Transurethral needle delivery device with cystoscope and method for treatment of urinary incontinence
AU707866B2 (en) 1994-12-06 1999-07-22 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
DE69629326D1 (de) 1995-02-15 2003-09-11 Joseph Eldor Spinalnadel mit mehreren Löchern
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US5688676A (en) 1995-06-07 1997-11-18 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6506379B1 (en) 1995-06-07 2003-01-14 Ariad Gene Therapeutics, Inc. Intramuscular delivery of recombinant AAV
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
EP0931158A1 (fr) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania Procede inductible de production de virus adeno-associes recombines au moyen de la polymerase t7
EP0932694A2 (fr) 1996-09-11 1999-08-04 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Vecteur de vaa4 et ses utilisations
US5865744A (en) 1996-09-16 1999-02-02 Lemelson; Jerome H. Method and system for delivering therapeutic agents
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
EP0950091A2 (fr) 1996-12-18 1999-10-20 Targeted Genetics Corporation Genes d'encapsidation fractionnes de virus adeno-associe (aav) et lignees cellulaires comprenant ces genes utilises pour la production de vecteurs d'aav de recombinaison
US5759179A (en) 1996-12-31 1998-06-02 Johnson & Johnson Medical, Inc. Needle and valve assembly for use with a catheter
WO1998046273A2 (fr) 1997-04-17 1998-10-22 Paola Leone Systeme d'administration d'une therapie genique au cerveau
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
WO1999015685A1 (fr) 1997-09-19 1999-04-01 The Trustees Of The University Of Pennsylvania Procedes et lignee cellulaire utiles pour la production de virus adeno-associes recombines
WO1999014354A1 (fr) 1997-09-19 1999-03-25 The Trustees Of The University Of The Pennsylvania Procedes et produits genetiques vectoriels utiles pour obtenir un virus adeno-associe (aav)
WO1999047691A1 (fr) 1998-03-20 1999-09-23 Trustees Of The University Of Pennsylvania Compositions et methodes de production de virus adeno-associes recombines sans auxiliaire
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
ES2257051T3 (es) * 1998-05-27 2006-07-16 Avigen, Inc. Administracion potenciada por conveccion de vectores aav que codifican aadc.
EP1621626B1 (fr) * 1998-05-27 2009-07-08 Genzyme Corporation Vecteurs AAV pour la fabrication des médicaments pour l'administration amélioré par la convection
GB9817662D0 (en) 1998-08-13 1998-10-07 Crocker Peter J Substance delivery
EP1124976A1 (fr) 1998-10-27 2001-08-22 Crucell Holland B.V. Production amelioree de vecteurs de virus associes aux adenovirus
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
AU2409200A (en) 1999-06-02 2000-12-28 Trustees Of The University Of Pennsylvania, The Compositions and methods useful for production of recombinant viruses which require helper viruses
US6365394B1 (en) 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
WO2001023001A2 (fr) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Procedes de modification rapide du peg de vecteurs viraux, compositions servant a ameliorer la transduction de genes, compositions presentant une stabilite physique augmentee, et leurs utilisations
US6613026B1 (en) 1999-12-08 2003-09-02 Scimed Life Systems, Inc. Lateral needle-less injection apparatus and method
US6726659B1 (en) 1999-12-09 2004-04-27 John E. Stocking Catheter assembly having a fenestrated dilator
US6382212B1 (en) 2000-01-18 2002-05-07 Medtronic, Inc. Fenestrated surgical drape with in situ features
US6565572B2 (en) 2000-04-10 2003-05-20 Sdgi Holdings, Inc. Fenestrated surgical screw and method
US6780409B2 (en) 2000-05-23 2004-08-24 Thomas Jefferson University Glutamic acid decarboxylase (GAD) based delivery system
US7588757B2 (en) 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
US6520949B2 (en) 2001-04-02 2003-02-18 Martin St. Germain Method and apparatus for administering fluid to animals subcutaneously
EP2017338A1 (fr) 2001-05-24 2009-01-21 Genzyme Corporation Vecteurs d'expression spécifiques au muscle
PL220644B1 (pl) 2001-11-13 2015-11-30 Univ Pennsylvania Wirus stowarzyszony z adenowirusem (AAV), kompozycja, wyizolowane białko kapsydowe, wyizolowane lub syntetyczne cząsteczki kwasu nukleinowego, sposób wytwarzania zrekombinowanego wirusa, komórka gospodarza
EP2573170B1 (fr) 2001-12-17 2017-12-20 The Trustees Of The University Of Pennsylvania Séquences de sérotype 9 de virus adéno-associé, vecteurs les contenant et leurs utilisations
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
WO2005017101A2 (fr) 2003-05-19 2005-02-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH Virus aviaire adenoassocie (aaav) et ses utilisations
SI2277996T1 (sl) 2003-05-21 2014-12-31 Genzyme Corporation Postopki za izdelavo pripravkov rekombinantnih AAV virionov v bistvu brez praznih kapsid
DK1633772T3 (en) 2003-06-19 2016-02-29 Avigen Inc AAV virions WITH REDUCED immunoreactivity AND USES THEREOF
ES2478625T3 (es) 2003-06-20 2014-07-22 The Trustees Of The University Of Pennsylvania Método de generación de adenovirus quiméricos y usos de tales adenovirus quiméricos
US7291498B2 (en) 2003-06-20 2007-11-06 The Trustees Of The University Of Pennsylvania Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US8333734B2 (en) 2003-07-03 2012-12-18 Walter A. Zohmann Fenestrated peripheral nerve block needle and method for using the same
US7575572B2 (en) 2003-07-15 2009-08-18 Spinal Generations, Llc Method and device for delivering medicine to bone
HUE033158T2 (en) 2003-09-30 2017-11-28 Univ Pennsylvania Adeno-associated virus (AAV) clusters, sequences, vectors containing them, and their use
US7135010B2 (en) 2003-09-30 2006-11-14 Damage Control Surgical Technologies, Inc. Method and apparatus for rapid deployment chest drainage
US7699852B2 (en) 2003-11-19 2010-04-20 Zimmer Spine, Inc. Fenestrated bone tap and method
WO2005056807A2 (fr) 2003-12-04 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Vecteur viral associe aux adenovirus bovins et leurs utilisations
WO2005072364A2 (fr) 2004-01-27 2005-08-11 University Of Florida Systeme d'expression baculovirus modifie utilise pour la production d'un vecteur raav pseudotype
US7427396B2 (en) 2004-06-03 2008-09-23 Genzyme Corporation AAV vectors for gene delivery to the lung
EP1866422B1 (fr) 2005-04-07 2016-04-06 The Trustees of The University of Pennsylvania Procede d'augmentation de la fonction d'un vecteur aav
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
EP1857552A1 (fr) 2006-05-20 2007-11-21 Cargill Incorporated Xylose isomérase thermostable
EP2311967B1 (fr) 2005-10-20 2017-09-20 UniQure IP B.V. Vecteurs viraux adéno-associés améliorés, produits en cellules d'insecte
EP1956975A2 (fr) 2005-11-29 2008-08-20 Surgi-Vision, Inc. Systèmes de mise en place de dérivation et/ou de localisation guidés par irm et procédés, dispositifs et programmes informatiques associés
EP2007795B1 (fr) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Protéines de capsides aav
DK2152346T3 (en) 2007-05-17 2016-01-18 Medgenesis Therapeutix Inc Konvektionsforstærket indgivelseskateter with removable support element
US20100203083A1 (en) 2007-05-31 2010-08-12 Medigene Ag Mutated structural protein of a parvovirus
US8374677B2 (en) 2007-06-07 2013-02-12 MRI Interventions, Inc. MRI-guided medical interventional systems and methods
US8175677B2 (en) 2007-06-07 2012-05-08 MRI Interventions, Inc. MRI-guided medical interventional systems and methods
EP2019143A1 (fr) 2007-07-23 2009-01-28 Genethon Thérapie génique du CNS utilisant l'administration périphérique de vecteurs AAV
US8099150B2 (en) 2007-09-24 2012-01-17 MRI Interventions, Inc. MRI-compatible head fixation frame with cooperating head coil apparatus
US8548569B2 (en) 2007-09-24 2013-10-01 MRI Interventions, Inc. Head fixation assemblies for medical procedures
EP2058401A1 (fr) 2007-10-05 2009-05-13 Genethon Fourniture généralisée de gènes à des motoneurones utilisant l'injection périphérique de vecteurs AAV
WO2009067205A1 (fr) 2007-11-21 2009-05-28 Surgi-Vision, Inc. Procédés, systèmes et programmes informatiques pour le positionnement d'un appareil de guidage par rapport à un patient
CN102159713A (zh) 2008-05-20 2011-08-17 Eos神经科学公司 用于递送光敏蛋白的载体和使用方法
US8889641B2 (en) 2009-02-11 2014-11-18 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
WO2010138263A2 (fr) 2009-05-28 2010-12-02 University Of Massachusetts Nouveaux virus adéno-associés (aav) et leurs utilisations
JP2012529977A (ja) 2009-06-16 2012-11-29 エムアールアイ・インターヴェンションズ，インコーポレイテッド Ｍｒｉ誘導装置、及び準リアルタイムに該装置を追跡し、該装置の動的可視化を生成することができるｍｒｉ誘導介入システム
US8679479B2 (en) 2009-06-29 2014-03-25 Aerase, Inc. Methods for purifying pegylated arginase
WO2011101869A1 (fr) 2010-02-22 2011-08-25 Transgene Biotek Ltd. Traitement contre le cancer du foie impliquant l'adénovirus associé 2/8 et le micro-arn 101
WO2011117258A2 (fr) 2010-03-22 2011-09-29 Association Institut De Myologie Procédés d'augmentation de l'efficacité de pénétration d'un vecteur dans un tissu cible
US10105485B2 (en) 2010-04-16 2018-10-23 MRI Interventions, Inc. MRI surgical systems including MRI-compatible surgical cannulae for transferring a substance to and/or from a patient
CA2833908C (fr) 2010-04-23 2021-02-09 University Of Massachusetts Vecteurs aav ciblant le systeme nerveux central et leurs procedes d'utilisation
EP2394667A1 (fr) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vecteurs et séquences pour le traitement de maladies
JP5704361B2 (ja) 2010-10-27 2015-04-22 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
US20140024909A1 (en) 2011-02-24 2014-01-23 MRI Interventions, Inc. Mri-guided catheters
US20120295960A1 (en) * 2011-05-20 2012-11-22 Oxford Biomedica (Uk) Ltd. Treatment regimen for parkinson's disease
WO2013019830A2 (fr) 2011-08-01 2013-02-07 Alcyone Lifesciences, Inc. Dispositifs microfluidiques d'administration de médicament
ES2857773T3 (es) 2011-08-24 2021-09-29 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
US20140359799A1 (en) 2011-12-23 2014-12-04 Case Western Reserve University Targeted gene modification using hybrid recombinant adeno-associated virus
US9192393B2 (en) 2012-05-31 2015-11-24 MRI Interventions, Inc. MRI compatible surgical drills and related methods
US10206693B2 (en) 2012-07-19 2019-02-19 MRI Interventions, Inc. MRI-guided medical interventional systems and methods
US9498290B2 (en) 2012-07-19 2016-11-22 MRI Interventions, Inc. Surgical navigation devices and methods
US9031636B2 (en) 2012-07-19 2015-05-12 MRI Interventions, Inc. MRI-compatible head fixation apparatus
US9192446B2 (en) 2012-09-05 2015-11-24 MRI Interventions, Inc. Trajectory guide frame for MRI-guided surgeries
CA2885544A1 (fr) 2012-09-28 2014-04-03 The University Of North Carolina At Chapel Hill Vecteurs vaa cibles sur des oligodendrocytes
DK2954051T3 (da) 2013-02-08 2019-07-08 Univ Pennsylvania Modificeret kapsid til genoverførsel til behandling af nethinden
US10421949B2 (en) 2013-02-22 2019-09-24 Genzyme Corporation Microcarrier perfusion culturing methods and uses thereof
US9572928B2 (en) 2013-03-13 2017-02-21 MRI Interventions, Inc. Substance delivery devices, systems and methods
US9498575B2 (en) 2013-03-14 2016-11-22 MRI Interventions, Inc. Substance delivery devices, systems and methods
PT2968605T (pt) 2013-03-15 2022-09-22 Univ North Carolina Chapel Hill Métodos e composições para vetores aav de ligação dupla de glicano
US9618590B2 (en) 2013-03-15 2017-04-11 MRI Interventions, Inc. Tip assembly for MRI-compatible medical devices and MRI-compatible medical devices incorporating same
TWI500551B (zh) 2013-04-26 2015-09-21 Ful Chee Ent Co Ltd Bicycle quick release structure
MX2015015244A (es) 2013-05-01 2016-07-05 Genzyme Corp Composiciones y metodos para tratar la atrofia muscular espinal.
WO2014194132A1 (fr) 2013-05-31 2014-12-04 The Regents Of The University Of California Variants de virus adéno-associés et leurs méthodes d'utilisation
EP3561062A1 (fr) 2013-09-13 2019-10-30 California Institute of Technology Récupération sélective
AU2014324717B2 (en) 2013-09-26 2020-10-08 University Of Florida Research Foundation, Inc. Synthetic combinatorial AAV capsid library for targeted gene therapy
WO2015057807A1 (fr) 2013-10-16 2015-04-23 MRI Interventions, Inc. Systèmes chirurgicaux de navigation, dispositifs et méthodes associés
US10087224B2 (en) 2013-11-01 2018-10-02 Cornell University Gene therapy for Alzheimer's and other neurodegenerative diseases and conditions
US10595744B2 (en) 2014-02-14 2020-03-24 MRI Interventions, Inc. Surgical tool-positioning devices and related methods
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
ES2879636T3 (es) 2014-05-02 2021-11-22 Genzyme Corp Vectores AAV para la terapia génica de la retina y el SNC
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
KR20230067694A (ko) 2014-09-24 2023-05-16 시티 오브 호프 고효율 게놈 편집을 위한 아데노-관련 바이러스 벡터 변이체 및 이의 방법
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
SG10202007103TA (en) * 2014-11-05 2020-09-29 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
TN2017000354A1 (en) 2015-02-10 2019-01-16 Genzyme Corp VARIANT RNAi
US20180135074A1 (en) * 2015-02-19 2018-05-17 University Of Florida Research Foundation, Incorporated Recombinant aav vectors for gene therapy of human hematopoietic disorders
BR112017017867A2 (pt) 2015-02-20 2018-04-10 Fond Telethon métodos e composições para tratamento de doenças oculares genéticas
US20180216133A1 (en) 2015-07-17 2018-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for achieving high levels of transduction in human liver cells
WO2017023724A1 (fr) * 2015-07-31 2017-02-09 Voyager Therapeutics, Inc. Compositions et méthodes pour le traitement d'une déficience en aadc
ES2865487T3 (es) 2015-09-28 2021-10-15 Univ North Carolina Chapel Hill Métodos y composiciones para vectores virales que evaden los anticuerpos
WO2017066764A2 (fr) 2015-10-16 2017-04-20 William Marsh Rice University Modification de la région n-terminale des protéines de capsides pour améliorer les propriétés des virus adéno-associés
EP3374494A4 (fr) 2015-11-11 2019-05-01 Coda Biotherapeutics, Inc. Compositions crispr et leurs méthodes d'utilisation pour la thérapie génique
US10240145B2 (en) 2015-11-25 2019-03-26 The Board Of Trustees Of The Leland Stanford Junior University CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer
WO2017100671A1 (fr) 2015-12-11 2017-06-15 California Institute Of Technology Peptides de ciblage pour diriger des virus adéno-associés (aav)
JOP20190269A1 (ar) * 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
AU2019257755A1 (en) * 2018-04-27 2020-11-12 Voyager Therapeutics, Inc. Methods for measuring the potency of AADC viral vectors
US20230242939A1 (en) * 2020-01-29 2023-08-03 Voyager Therapeutics, Inc. Methods and systems for producing aav particles

Also Published As

Publication number Publication date
CN112424359A (zh) 2021-02-26
AU2019268330A1 (en) 2020-11-26
MX2020012077A (es) 2021-03-09
SG11202011296VA (en) 2020-12-30
KR20210019996A (ko) 2021-02-23
WO2019222328A1 (fr) 2019-11-21
JP2021523914A (ja) 2021-09-09
TW202012628A (zh) 2020-04-01
CA3099306A1 (fr) 2019-11-21
EP3794126A1 (fr) 2021-03-24
BR112020023082A2 (pt) 2021-02-09
US20210198691A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA49402A (fr) Polynucléotides aadc pour le traitement de la maladie de parkinson
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA54792A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA52861A (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA53661A (fr) Agonistes du récepteur farnésoïde x pour le traitement d'une maladie
MA50800A (fr) Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MA47504A (fr) Composés et méthodes de traitement de l'angiocholite biliaire primitive
MA53329A (fr) Méthodes de traitement de l'épilepsie
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA54132A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
MA44864A (fr) Trithérapie pour le traitement d'une maladie intestinale inflammatoire
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA49131A (fr) Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire
MA45997A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d
MA41629A (fr) Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
IL288894A (en) Methods for the assessment and treatment of Alzheimer's disease and their applications